Another Nail in the Coffin for Anti-Amyloid Development in Alzheimer’s
Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for...
Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for...
This morning the FDA announced its approval of eteplirsen (brand name, Exonys 51) for the treatment of...
The annual costs of disease-modifying therapies (DMTs) for multiple sclerosis (MS) have increased at...
Gabrielle Strobel‘s comprehensive coverage of the phase 1 study of Biogen’s aducanumab, its...
Last week, the NYT, WSJ, and Wall Street reacted enthusiastically, if not irrationally, to results of a...
Sometime in early January, I starting wondering about the status of TRx0237 (aka methylthioninium chloride...